The Queens-Long Island Renal Institute (QLIRI) at Parker Jewish Institute for Health Care and Rehabilitation was recently honored with two quality recognition awards, by the Island Peer Review Organization End-Stage Renal Disease Network of New York.
These prestigious awards represent programs from across the state that demonstrates excellence in best practices in response to a public health need.
“The QLIRI team accomplished this wonderful goal, very diligently, to help support patient care,” said Michael N. Rosenblut, QLIRI’s President and CEO.
QLIRI earned the “Recognition of Excellence in Medication Management Initiative: CMS Emerging Success Story,” for its education programs and awareness campaigns to support medication management, opioid misuse counseling, and substance abuse screenings. These initiatives were identified as best practice strategies in opioid-misuse prevention and treatment as well as supporting safe and effective pain management, according to the network.
QLIRI was also awarded the “Recognition of Achievement in the ESRD Quality Incentive Program (QIP) Arteriovenous Fistula (AVF)/Graft (AVG) 2018 Performance Score,” having achieved the highest rating, 10 points, in this category, according to the network.
These awards are just some of the recent recognitions earned by Queens-Long Island Renal Institute. The organization also received the prestigious 5-Diamond Patient Safety Program. This award is given only to those dialysis facilities that meet precise criteria. These standards include building specific staff and patient awareness of defined patient safety areas, promoting patient safety values, and fostering a culture of patient safety after completing a series of learning modules.
Submitted by the Parker Jewish Institute for Health Care and Rehabilitation
